(PPH) VanEck Pharmaceutical - Ratings and Ratios
Pharmaceuticals, Drugs, Medications, Biotechnology, Healthcare
Description: PPH VanEck Pharmaceutical
The VanEck Pharmaceutical ETF (NASDAQ:PPH) is an investment fund that focuses on the pharmaceutical sector, tracking a benchmark index comprising common stocks and depositary receipts of U.S. exchange-listed companies. The funds portfolio may include medium-capitalization companies and foreign entities listed on U.S. exchanges, indicating a potentially diverse exposure within the pharmaceutical industry.
By investing at least 80% of its total assets in securities that make up its benchmark index, the fund aims to replicate the performance of the pharmaceutical sector. Given its non-diversified nature, the funds performance is closely tied to the overall health and trends within the pharmaceutical industry, making it a targeted investment for those looking to capitalize on this sector.
From a technical standpoint, analyzing the funds recent price movements and trends can provide insights into its potential future performance. With a last price of $87.93, the fund is currently below its 20-day Simple Moving Average (SMA) of $88.76 but above its 50-day SMA of $87.13. This indicates a potential short-term downward trend, while the longer-term trend remains positive. The funds price is also below its 200-day SMA of $89.12, suggesting that it is currently in a correction phase. The Average True Range (ATR) of 1.18, or 1.34%, indicates moderate volatility.
Considering the funds Assets Under Management (AUM) of $560.98M USD, it has a substantial presence in the market, which can contribute to liquidity and potentially reduce the impact of individual stock volatility on the overall fund performance. The pharmaceutical industry is known for its stability and growth, driven by continuous demand for healthcare products and innovation.
Forecasting the funds future performance involves analyzing both technical indicators and fundamental data. Given the current technical trends and the funds position relative to its SMAs, a potential short-term target could be a return to the 20-day SMA at $88.76. In the longer term, if the pharmaceutical industry continues to grow and the fund maintains its tracking of the benchmark index, we could see the funds price move towards or beyond its 52-week high of $97.97, assuming the industry trends remain favorable. However, any forecast is contingent upon the funds ability to track its index closely and the overall performance of the pharmaceutical sector.
Investors should closely monitor industry trends, regulatory changes, and the funds tracking efficiency to make informed decisions. The non-diversified nature of the fund means that sector-specific risks are more pronounced, and any adverse developments in the pharmaceutical industry could negatively impact the funds performance.
PPH ETF Overview
| Market Cap in USD | 626m |
| Category | Health |
| TER | 0.36% |
| IPO / Inception | 2011-12-20 |
PPH ETF Ratings
| Growth Rating | 30.9% |
| Fundamental | - |
| Dividend Rating | 60.7% |
| Return 12m vs S&P 500 | -22.8% |
| Analyst Rating | - |
PPH Dividends
| Dividend Yield 12m | 2.21% |
| Yield on Cost 5y | 3.39% |
| Annual Growth 5y | 9.13% |
| Payout Consistency | 93.5% |
| Payout Ratio | % |
PPH Growth Ratios
| Growth Correlation 3m | 28.9% |
| Growth Correlation 12m | -32.5% |
| Growth Correlation 5y | 92.4% |
| CAGR 5y | 10.28% |
| CAGR/Max DD 3y | 0.57 |
| CAGR/Mean DD 3y | 3.24 |
| Sharpe Ratio 12m | -0.24 |
| Alpha | -26.79 |
| Beta | 0.940 |
| Volatility | 14.37% |
| Current Volume | 192.1k |
| Average Volume 20d | 204.3k |
| Stop Loss | 85.6 (-3%) |
| Signal | -0.80 |
What is the price of PPH shares?
Over the past week, the price has changed by -0.81%, over one month by +1.06%, over three months by -1.28% and over the past year by -8.22%.
Is VanEck Pharmaceutical a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of PPH is around 85.90 USD . This means that PPH is currently overvalued and has a potential downside of -2.7%.
Is PPH a buy, sell or hold?
What are the forecasts/targets for the PPH price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 96.6 | 9.4% |
Last update: 2025-09-05 04:56
PPH Fundamental Data Overview
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 USD
Beta = 0.61
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 625.6m USD (625.6m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 625.6m)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 625.6m / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default)
NOPAT = 0.0 (EBIT 0.0, no tax applied on loss)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(625.6m)/V(0.0) * Re(9.48%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 9.48% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for PPH ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle